Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

4

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclooxygenase-2

4

GO:0004144 diacylglycerol O-acyltransferase activity

4

GO:0004465 lipoprotein lipase activity

4

Peroxisome proliferator-activated receptor delta

4

Peroxisome proliferator-activated receptor gamma

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2008

4

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Alzheimer’s disease

4

Hypertriglyceridemia

4

Major depressive disorder

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Scarista

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

FDA UNII

5

PUBCHEM

4

DRUG BANK

3

EPA CompTox

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ICOSAPENT

AAN7QOV9EA

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First approved in 2008

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

fatty acid beta-oxidation

GO:0004465 lipoprotein lipase activity

GO:0004144 diacylglycerol O-acyltransferase activity

Peroxisome proliferator-activated receptor gamma

lipoprotein oxidation

transformed cell apoptotic process

Receptor-mediated non-selective cation current (Icat)

Peroxisome proliferator-activated receptor delta

Prolyl endopeptidase

Cyclooxygenase-2

Conditions:

Hypertriglyceridemia

Major depressive disorder

Alzheimer’s disease

Icosapent is an important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardio...

vascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.

2,4,6,8,10-EICOSAPENTAENOIC ACID, (2E,4E,6E,8E,10E)-

NT3H35FB86

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Icosapent lysine salt

XX8KWN4FNB

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First approved in 2008

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

fatty acid beta-oxidation

GO:0004465 lipoprotein lipase activity

GO:0004144 diacylglycerol O-acyltransferase activity

Peroxisome proliferator-activated receptor gamma

lipoprotein oxidation

transformed cell apoptotic process

Receptor-mediated non-selective cation current (Icat)

Peroxisome proliferator-activated receptor delta

Prolyl endopeptidase

Cyclooxygenase-2

Conditions:

Hypertriglyceridemia

Major depressive disorder

Alzheimer’s disease

Icosapent is an important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardio...

vascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.

ICOSAPENT SODIUM

5PXN91KPRO

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First approved in 2008

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

fatty acid beta-oxidation

GO:0004465 lipoprotein lipase activity

GO:0004144 diacylglycerol O-acyltransferase activity

Peroxisome proliferator-activated receptor gamma

lipoprotein oxidation

transformed cell apoptotic process

Receptor-mediated non-selective cation current (Icat)

Peroxisome proliferator-activated receptor delta

Prolyl endopeptidase

Cyclooxygenase-2

Conditions:

Hypertriglyceridemia

Major depressive disorder

Alzheimer’s disease

Icosapent is an important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardio...

vascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.

ICOSAPENT ETHYL

6GC8A4PAYH

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First approved in 2008

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

fatty acid beta-oxidation

GO:0004465 lipoprotein lipase activity

GO:0004144 diacylglycerol O-acyltransferase activity

Peroxisome proliferator-activated receptor gamma

lipoprotein oxidation

transformed cell apoptotic process

Receptor-mediated non-selective cation current (Icat)

Peroxisome proliferator-activated receptor delta

Prolyl endopeptidase

Cyclooxygenase-2

Conditions:

Hypertriglyceridemia

Major depressive disorder

Alzheimer’s disease

Icosapent is an important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardio...

vascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1